Endo grabs Aspen branded, generic meds; Ironwood, Actavis sponsor IBS survey;

> Endo International ($ENDP) snapped up a portfolio of branded and generic products from Aspen, expanding its presence in that company's home country of South Africa. Release

> Ironwood Pharmaceuticals and Actavis ($ACT) are sponsoring a broad survey of patients with irritable bowel syndrome, under the auspices of the American Gastroenterological Association. Release

> Spain's Almirall racked up €217 million in first-quarter sales, including a milestone payment from AstraZeneca ($AZN) stemming from a respiratory drug deal last year. Release

> Roche ($RHHBY) will roll out new pivotal data on its cancer drug Gazyva in non-Hodgkin's lymphoma and the as-yet-unapproved ALK inhibitor alectinib in non-small-cell lung cancer at the American Society for Clinical Oncology meeting later this month. Release

And Finally... The New Yorker returned to McAllen, TX, to find that the notoriously high-spending market has cut its health expenses substantially. Report

Suggested Articles

A small group of physicians expressed little interest in new MS drugs from Novartis, Merck KGaA and Biogen but favored a repurposed therapy.

Sanofi and Regeneron recently debuted an unbranded awareness and education campaign around type 2 inflammation and its connections across conditions.

Amgen could soon face new competition in the PCSK9 class, but an efficacy boost in treating high-risk heart attack patients could help keep it ahead.